AstraZeneca in Talks to Shift Coronavirus Vaccine Production to Catalent’s Maryland Factory
AstraZeneca is reportedly in talks to shift production of its coronavirus vaccine to a Maryland-based factory operated by Catalent, Inc.
The New York Times reported that the British drugmaker is in negotiations with the federal government to to retrofit a production line after embattled drugmaker Emergent BioSolutions was forced to stop manufacturing the vaccine at a plant in Baltimore.
AstraZeneca was awarded a $1.2 billion contract last May from the federal government for clinical trials and for production of 300 million doses of the vaccine.
A federal official told The Times that the government was negotiating its contract to shift production of the vaccine from Emergent to Catalent.
Catalent currently produces AstraZenca’s vaccine for export.
Holly Campbell, a spokeswoman for AstraZeneca told The Times “we can confirm we are working with Catalent but have not disclosed specific details on supply.” A spokesperson for Catalent declined to comment to the newspaper.
Click here to read more via The Hill.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
